BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh

 You are in: Health
Front Page 
UK Politics 
Background Briefings 
Medical notes 
Talking Point 
In Depth 

Commonwealth Games 2002

BBC Sport

BBC Weather

Monday, 13 August, 2001, 22:05 GMT 23:05 UK
Drug slows Alzheimer's progress
Aricept is proving to be an effective treatment for Alzheimer's disease
Researchers have produced compelling evidence of the positive impact of the Alzheimer's drug Aricept.

They have shown that patients who take the drug, technical name donepezil, are able to carry out everyday activities for much longer than other Alzheimer's patients.

US researchers carried out tests on 415 people with Alzheimer's. Some were given donepezil, and others a placebo.

Those who took donepezil were able to carry out everyday activities such as shopping for an average of five months longer than patients who took a placebo.

The researchers measured the amount of time before patients' functioning declined based on a clinical rating scale.

The lead researcher was Dr Richard Mohs, of the Mount Sinai School of Medicine and Bronx VA Medical Center in Bronx, New York.

He said: "For Alzheimer's patients and their families, five months can mean another birthday celebration or another holiday, and five months more that they can stay in their own homes."

Most studies of donepezil have looked at its effects on the way the brain works rather than level of functioning in daily activities.

Dr Mohs said: "This shows that in addition to helping people preserve their ability to learn new information and remember what they've learned, donepezil also helps preserve their ability to do the laundry and enjoy their hobbies - the things that help them stay independent and maintain their quality of life."

Second study

The results were echoed by a second separate study which found that Alzheimer's patients who took donepezil declined at about half the rate of those taking a placebo.

The one-year study involved 286 people in Scandinavia and the Netherlands.

Researcher Dr Bengt Winblad, of the Karolinska Institute, Alzheimer's Disease Research Center in Stockholm, Sweden, said: "These results show that donepezil is an effective treatment in the long-term and demonstrate the importance of continued donepezil treatment for optimal benefits in patients with mild to moderate Alzheimer's disease."

Alzheimer's patients lose brain cells that produce acetylcholine, a chemical that carries messages between brain nerve cells.

Donepezil blocks the chemical breakdown of acetylcholine.

The National Institute for Clinical Excellence ruled in January that Aricept, and two other Alzheimer's drugs, should be made freely available on the NHS.

The research was published in Neurology, the scientific journal of the American Academy of Neurology.

See also:

20 Dec 00 | A-B
Alzheimer's disease
30 May 01 | Health
Minister steps into drugs row
Internet links:

The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.

E-mail this story to a friend

Links to more Health stories